metaEvidence - overview


			DCR
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus gp100
	ipilimumab alone vs. gp100	1	-
	ipilimumab plus gp100 vs. gp100	1	-
versus ipilimumab alone
	Ipilimumab (10 mg/kg) vs. ipilimumab alone	1
	ipilimumab plus gp100 vs. ipilimumab alone	1	-
	pembrolizumab (10mg/kg) vs. ipilimumab alone	1	-
	pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone	1	-
versus placebo plus SoC
	ipilimumab plus SoC vs. placebo plus SoC	1
versus Standard of Care (SoC)
	nivolumab alone vs. Standard of Care (SoC)	1	-
	pembrolizumab (10mg/kg) vs. Standard of Care (SoC)	1	-
	pembrolizumab (2mg/kg) vs. Standard of Care (SoC)	1	-
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1	-